HLB Innovation's Verismo to Unveil Preclinical Results for Solid Tumor CAR-T
Verismo Therapeutics, a U.S. subsidiary of HLB Innovation, will present preclinical results for its solid tumor CAR-T therapy at the Society for Immunotherapy of Cancer (SITC 2026) on November 6 (local time).
According to Verismo on October 16, the study compared the company’s multichain KIR-CAR T with single-chain CAR-T therapies based on CD28 or 4-1BB, which are commonly used in conventional CAR-T treatments, in vivo in preclinical models.
Unlike conventional CAR-T therapies, Verismo’s KIR-CAR uses a multichain structure that mimics the natural receptor structure of immune cells. While conventional CAR-T therapies combine the components needed for antigen recognition and T-cell activation into a single chain, KIR-CAR uses the KIR structure of natural killer (NK) cells, separating the antigen-binding and signaling components. The two components are designed to remain separate under normal conditions and bind to each other when they recognize a target antigen on a cancer cell, thereby triggering T-cell activation signals.
The mesothelin-targeting KIR-CAR used in this study is based on the technology used in SynKIR-110, which is currently undergoing a Phase 1 clinical trial in the United States. The preclinical results support the clinical development of SynKIR-110, which is being developed for patients with advanced solid tumors that express mesothelin, including ovarian cancer, cholangiocarcinoma and mesothelioma.
Hot Picks Today
'Big Investor' NPS Has Already Cut Its Losses... Sold Department Store Stocks in Q3 Despite Strong Earnings Outlook
- "Female Teachers Must Wear Skirts in Class"... Outrage Erupts Over Principal's Demand: What's Happening in North Korea?
- "It's Hard to Breathe": Worst Wildfires Force School Closures... "15 Times the Size of Seoul Reduced to Ashes"
- "I Put in 10 Million Won, but Only 2 Million Won Is Left" ... 77% Plunge Leaves Retail Investors in Samsung Electronics and SK hynix Leveraged ETFs Crying Out
- "The leggings are all see-through. It's so embarrassing to look at," complaints prompt Lululemon to fire development staff.
Brian Kim, CEO and co-founder of Verismo Therapeutics, said, "This study is significant because a direct comparison with conventional CAR-T therapies confirmed in vivo that the multichain KIR-CAR has distinct advantages in reducing T-cell exhaustion and cytokine release. We will continue developing SynKIR-110, which is currently in a Phase 1 clinical trial, and open up new possibilities for CAR-T treatment of solid tumors."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
